Search results for "transfusion"

showing 10 items of 177 documents

Overcoming barriers to evidence-based patient blood management: a restricted review

2020

Abstract Background Blood transfusions are associated with a range of adverse patient outcomes, including coagulopathy, immunomodulation and haemolysis, which increase the risk of morbidity and mortality. Consideration of these risks and potential benefits are necessary when deciding to transfuse. Patient blood management (PBM) guidelines exist to assist in clinical decision-making, but they are underutilised. Exploration of barriers to the implementation and utilisation of the PBM guidelines is required. This study aimed to identify common barriers and implementation strategies used to implement PBM guidelines, with a comparison against current expert opinion. Methods A restricted review a…

Health Knowledge Attitudes PracticeEvidence-based practiceMEDLINEHealth Informatics030204 cardiovascular system & hematologyCochrane LibraryHealth informaticsImplementation StrategiesConsolidated Framework for Implementation ResearchHealth administration03 medical and health sciences0302 clinical medicineNursingExpert Recommendations for Implementing ChangePatient blood managementMedicineHumansBlood Transfusion030212 general & internal medicineImplementation Sciencelcsh:R5-920business.industryHealth PolicyPublic Health Environmental and Occupational HealthHealth services researchGeneral MedicineHaemolysisOrganizational CultureVDP::Medisinske Fag: 700::Helsefag: 800Practice Guidelines as TopicBarrier MappingImplementation researchSystematic ReviewGuideline Adherencebusinesslcsh:Medicine (General)
researchProduct

Transmission of human immunodeficiency virus Type-1 by fresh-frozen plasma treated with methylene blue and light

2015

BACKGROUND The risk of transfusion-transmitted infection (TTI) has been minimized by introduction of nucleic acid testing (NAT) and pathogen inactivation (PI). This case report describes transmission of human immunodeficiency virus Type 1 (HIV-1) to two recipients despite these measures. STUDY DESIGN AND METHODS In March 2009 a possible TTI of HIV-1 was identified in a patient that had received pooled buffy coat platelet concentrate (BC-PLT) in November 2005. The subsequent lookback study found two more patients who had received methylene blue (MB)-treated fresh-frozen plasma (FFP) and red blood cells (RBCs) from the same donation. In November 2005 the donor had tested negative for both HIV…

ImmunologyRNAHematologyBuffy coatWindow period030204 cardiovascular system & hematologyBiologyVirologyVirus03 medical and health sciences0302 clinical medicineBlood Component Transfusionbiology.proteinImmunology and Allergy030212 general & internal medicineFresh frozen plasmaAntibodyViral loadTransfusion
researchProduct

Interleukin-12 and -23 Control Plasticity of CD127(+) Group 1 and Group 3 Innate Lymphoid Cells in the Intestinal Lamina Propria.

2015

Human group 1 ILCs consist of at least three phenotypically distinct subsets, including NK cells, CD127(+) ILC1, and intraepithelial CD103(+) ILC1. In inflamed intestinal tissues from Crohn's disease patients, numbers of CD127(+) ILC1 increased at the cost of ILC3. Here we found that differentiation of ILC3 to CD127(+) ILC1 is reversible in vitro and in vivo. CD127(+) ILC1 differentiated to ILC3 in the presence of interleukin-2 (IL-2), IL-23, and IL-1β dependent on the transcription factor RORγt, and this process was enhanced in the presence of retinoic acid. Furthermore, we observed in resection specimen from Crohn's disease patients a higher proportion of CD14(+) dendritic cells (DC), whi…

Interleukin 2Receptors Retinoic AcidCellular differentiationCD14ImmunologyInterleukin-1betaRetinoic acidLipopolysaccharide Receptorschemical and pharmacologic phenomenaTretinoinMice SCIDBiologyInterleukin-12 Subunit p35Interleukin-7 Receptor alpha Subunitchemistry.chemical_compoundMiceIntestinal mucosaCrohn DiseaseMice Inbred NODmedicineImmunology and AllergyAnimalsHumansRetinoid X Receptor gammaLymphocytesIntestinal MucosaInterleukin-7 receptorCells CulturedMice KnockoutRetinoic Acid Receptor alphaInnate lymphoid cellvirus diseaseshemic and immune systemsCell DifferentiationDendritic CellsNuclear Receptor Subfamily 1 Group F Member 3Molecular biologyKiller Cells NaturalMice Inbred C57BLInfectious DiseaseschemistryLymphocyte TransfusionImmunologyInterleukin 12Interleukin-23 Subunit p19Interleukin-2medicine.drugImmunity
researchProduct

An Outbreak of Hepatitis C Virus Infection Among Transfused Thalassemia Patients: Root Cause Analysis, Phylogenetic Epidemiology and Antiviral Therapy

2021

Background: Occurrence of HCV infection is reduced by effective risk management procedures, but patient-to-patient transmission continues to be reported in healthcare settings. We report an outbreak of 11 patients with HCV acute hepatitis (seven new infections and four re-infections) among 128 thalassemia patients followed at a Hospital in Sicily. Methods All patients with acute hepatitis and known chronic infection were tested for HCV-RNA, HCV genotyping, and NS3, NS5A and NS5B HCV-genomic regions sequencing.  To identify transmission clusters we built phylogenetic trees for each gene employing Bayesian methods.  Findings All patients with acute hepatitis were infected with HCV genotype 1b…

Ledipasvirmedicine.medical_specialtyBlood transfusionSofosbuvirTransmission (medicine)business.industryHepatitis C virusmedicine.medical_treatmentmedicine.disease_causeHelsinki declarationchemistry.chemical_compoundChronic infectionchemistryInternal medicineEpidemiologymedicinebusinessmedicine.drugSSRN Electronic Journal
researchProduct

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – …

2013

International audience; Background & AimsIn phase III trials, the safety profile of triple therapy (pegylated interferon/ribavirin with boceprevir or telaprevir) seems to be similar in HCV treatment-experienced cirrhotic and non-cirrhotic patients, but few cirrhotics were included. We report the week 16 safety and efficacy analysis in a cohort of compensated cirrhotics treated in the French Early Access Programme.Methods674 genotype 1 patients, prospectively included, received 48 weeks of triple therapy. The analysis is restricted to 497 patients reaching week 16.ResultsA high incidence of serious adverse events (40.0%), and of death and severe complications (severe infection or hepatic dec…

Liver CirrhosisMaleCirrhosisBlood transfusionmedicine.medical_treatment[SDV]Life Sciences [q-bio]Chronic hepatitis CGastroenterologyTelaprevirTelaprevirCohort Studieschemistry.chemical_compound0302 clinical medicinePegylated interferonMedicineProspective StudiesAged 80 and overBoceprevirMiddle AgedViral Load3. Good healthTreatment OutcomeCirrhosis030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleFranceSafetyOligopeptidesmedicine.drugAdultmedicine.medical_specialtySerine Proteinase InhibitorsProlineAntiviral Agents03 medical and health sciencesInternal medicineBoceprevirRibavirinHumansAdverse effectAgedHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicmedicine.diseaseSurgeryTreatmentchemistrybusiness
researchProduct

Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia

2012

Eltrombopag is an oral thrombopoietin-receptor agonist. This study evaluated the efficacy of eltrombopag for increasing platelet counts and reducing the need for platelet transfusions in patients with thrombocytopenia and chronic liver disease who are undergoing an elective invasive procedure.We randomly assigned 292 patients with chronic liver disease of diverse causes and platelet counts of less than 50,000 per cubic millimeter to receive eltrombopag, at a dose of 75 mg daily, or placebo for 14 days before a planned elective invasive procedure that was performed within 5 days after the last dose. The primary end point was the avoidance of a platelet transfusion before, during, and up to 7…

Liver CirrhosisMaleCirrhosisChronic liver diseaseBenzoateslaw.inventionchemistry.chemical_compoundRandomized controlled triallawReceptorsClinical endpoint80 and overMedicineCIRRHOSISAged 80 and overBenzoic AcidsGeneral MedicineCHRONIC LIVER DISEASEMiddle AgedHydrazinesThrombopoietinElective Surgical ProceduresAnesthesiaFemaleElective Surgical ProcedureReceptors ThrombopoietinAdultAdolescentEltrombopagELTROMBOPAGHemorrhagePlatelet TransfusionPlaceboYoung AdultDouble-Blind MethodElectiveSurgical Procedures ElectiveHumansAgedTHROMBOCYTOPENIA; ELTROMBOPAG; CIRRHOSIS; CHRONIC LIVER DISEASESurgical Proceduresbusiness.industryPlatelet CountTHROMBOCYTOPENIAcirrhosisSettore MED/09 - MEDICINA INTERNAmedicine.diseaseThrombocytopeniaPlatelet transfusionchemistryChronic DiseasePyrazolesbusiness
researchProduct

Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression

2021

Abstract Background The universal treatment of diagnosed patients with chronic HCV infection has been widely conducted in Italy since 2017. However, the pool of individuals diagnosed but yet to be treated in Italy has been estimated to end around 2025, leaving a significant proportion of infected individuals undiagnosed/without care. Estimates of this population are currently unknown. Methods A probabilistic modelling approach was applied to estimate annual historical HCV incident cases by their age-group (0–100 years) distribution from available literature and Italian National database (1952 to October 2019). Viraemic infection rates were modelled on the main infection routes in Italy: peo…

Liver CirrhosisPediatricsBlood transfusionEpidemiologymedicine.medical_treatmentlaw.invention0302 clinical medicineFibrosislawEpidemiologyPrevalence030212 general & internal medicineStage (cooking)ChildSubstance Abuse IntravenousMonte CarloAged 80 and overeducation.field_of_studyMiddle AgedHepatitis CInfectious DiseasesTransmission (mechanics)ItalyChild PreschoolHCVmedicine.symptomModels Theoretical: Young AdultHumanAdultmedicine.medical_specialtySexual transmissionAdolescentLiver Cirrhosi030231 tropical medicinePopulationMarkov chainAntiviral AgentsMicrobiologyAsymptomaticlcsh:Infectious and parasitic diseasesYoung Adult03 medical and health sciencesVirologymedicineHumanslcsh:RC109-216Hepatitis C infectioneducationAgedAntiviral Agentbusiness.industryPublic Health Environmental and Occupational HealthInfant NewbornUndiagnosedInfantModels Theoreticalmedicine.diseaseParasitologybusiness
researchProduct

Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel.

2010

AbstractChelation therapy with new drugs prevents cardiac damage and improves the survival of thalassemia patients. Liver diseases have emerged as a critical clinical issue. Chronic liver diseases play an important role in the prognosis of thalassemia patients because of the high frequency of viral infections and important role of the liver in regulating iron metabolism. Accurate assessment of liver iron overload is required to tailor iron chelation therapy. The diagnosis of hepatitis B virus– or hepatitis C virus–related chronic hepatitis is required to detect patients who have a high risk of developing liver complications and who may benefit by antiviral therapy. Moreover, clinical manage…

Liver Cirrhosisthalassemiamedicine.medical_specialtyCirrhosisC VIRUS-INFECTION; HOMOZYGOUS BETA-THALASSEMIA; TRANSFUSION-DEPENDENT THALASSEMIA; TERM-FOLLOW-UP; IRON OVERLOAD; LIVER-DISEASE; INTERFERON-ALPHA; RISK-FACTORS; INTRAFAMILIAL TRANSMISSION; HEPATOCELLULAR-CARCINOMAHepatitis C virusThalassemiaImmunologymedicine.disease_causeChronic liver diseaseAntiviral AgentsBiochemistryHOMOZYGOUS BETA-THALASSEMIALiver diseaseHepatitis B ChronicLIVER-DISEASEHEPATOCELLULAR-CARCINOMAmedicineTRANSFUSION-DEPENDENT THALASSEMIAIRON OVERLOADHumansIntensive care medicineTERM-FOLLOW-UPchronic viral hepatitis; thalassemia; managementbusiness.industryCell BiologyHematologyHepatitis CHepatitis C ChronicHepatitis Bmedicine.diseaseINTRAFAMILIAL TRANSMISSIONchronic viral hepatitisImmunologyRISK-FACTORSINTERFERON-ALPHAViral hepatitisbusinessC VIRUS-INFECTIONmanagement
researchProduct

Transfusion sanguine. Responsabilité

1996

International audience; (Riom 6 avr. 1995, JCP 1995.4.325)

MEDECINEETABLISSEMENT DE SANTEClinique[SHS.DROIT]Humanities and Social Sciences/Law[SHS.DROIT] Humanities and Social Sciences/LawSIDATransfusion sanguineResponsabilité
researchProduct

Wnt3a Neutralization Enhances T-cell Responses through Indirect Mechanisms and Restrains Tumor Growth

2018

Abstract The Wnt/β-catenin pathway regulates T-cell functions, including the repression of effector functions to the advantage of memory development via Tcf1. In a companion study, we demonstrate that, in human cancers, Wnt3a/β-catenin signaling maintains tumor-infiltrating T cells in a partially exhausted status. Here, we have investigated the effects of Wnt3a neutralization in vivo in a mouse tumor model. Abundant Wnt3a was released, mostly by stromal cells, in the tumor microenvironment. We tested whether Wnt3a neutralization in vivo could rescue the effector capacity of tumor-infiltrating T cells, by administering an antibody to Wnt3a to tumor-bearing mice. This therapy restrained tumor…

Male0301 basic medicineCancer Researchanimal structuresStromal cellT cellmedicine.medical_treatmentImmunologyAdenocarcinomaCD8-Positive T-LymphocytesDendritic CellSettore MED/0403 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineImmunology; Cancer Research; Wnt; Beta-catenin.Cell Line TumorWnt3A ProteinmedicineAnimalsHumansWnt Signaling PathwayColonic NeoplasmTumor microenvironmentAnimalChemistryEffectorStromal CellWnt signaling pathwayCD8-Positive T-LymphocyteDendritic CellsImmunotherapyDendritic cellCell biologyMice Inbred C57BLbody regions030104 developmental biologymedicine.anatomical_structureLymphocyte Transfusion030220 oncology & carcinogenesisColonic Neoplasmsembryonic structuresImmunotherapyStromal CellsCD8HumanCancer Immunology Research
researchProduct